Micrograph News and Research

RSS

National clinical trial to test potential vaccine against SARS-CoV-2

UC San Diego Health and the Altman Clinical and Translational Research Institute, part of UC San Diego School of Medicine, will be sites for an accelerated national clinical trial to assess the efficacy and immunogenicity of a vaccine intended to protect against SARS-CoV-2, the novel coronavirus that causes COVID-19.

25 Jul 2020

Pfizer/BioNTech COVID-19 vaccine elicits both neutralizing antibodies and T cell response

A new study published on the preprint server medRxiv by a research group from the U.S. and Germany indicates that a novel BNT162b1 RNA-based vaccine against coronavirus disease (COVID-19) induces functional and proinflammatory T cell responses in almost all participants – marking another landmark achievement for this promising vaccine candidate.

21 Jul 2020

China's Ad5 vectored COVID-19 vaccine safe and induces immune response

A phase 2 trial of an Ad5 vectored COVID-19 vaccine candidate, conducted in China, has found that the vaccine is safe and induces an immune response, according to new research published in The Lancet.

20 Jul 2020

UC Riverside scientist to shed light on worm infections that escape detection by immune systems

It's likely that billions of people are unaware they have been infected with parasitic worms. A UC Riverside scientist has won $1.8 million to try and understand why.

20 Jul 2020

Hydroxychloroquine is not indicated for COVID-19 under any circumstances

The drug Hydroxychloroquine has long been studied as a treatment for malaria and autoimmune diseases. When the coronavirus pandemic spread across the globe, many countries resorted to using the drug in the hopes that it would improve outcomes of hospitalized patients affected by the coronavirus disease (COVID-19).

19 Jul 2020

Rapid genomic surveillance of healthcare-associated SARS-CoV-2

The researchers from the University of Cambridge, Cambridge United Kingdom have published their findings in a study titled, “Rapid implementation of SARS-CoV-2 sequencing to investigate cases of healthcare-associated COVID-19: a prospective genomic surveillance study,” in the latest issue of The Lancet Infectious Diseases.

16 Jul 2020

Selective statins may reduce SARS-CoV-2 cell entry and inhibit infection

Statins are a class of drugs often used to control high cholesterol levels in obesity. Now, a study published on the preprint server medRxiv* in July 2020 suggests that statins do not aggravate the risk of COVID-19 infection and may have a small beneficial effect in some cases.

16 Jul 2020

Moderna vaccine induces robust immune response against SARS-CoV-2

The race to develop an effective vaccine against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is on, and one of the potential candidates shows promise in inducing an immune response.

15 Jul 2020

Experimental vaccine induces neutralizing antibodies against SARS-CoV-2

An investigational vaccine, mRNA-1273, designed to protect against SARS-CoV-2, the virus that causes coronavirus disease 2019 (COVID-19), was generally well tolerated and prompted neutralizing antibody activity in healthy adults, according to interim results published online today in The New England Journal of Medicine.

15 Jul 2020

Cold sensitivity of SARS-CoV-2 could impact vaccine studies

Researchers at Duke University in Durham, USA, have made an important discovery about the spike protein on severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) that could have a broad impact on vaccine studies.

14 Jul 2020

Investigational antidepressant PT150 shows antiviral activity against SARS-CoV-2

In a recent bioRxiv study, an ad hoc multi-institutional research team from the US shows that a novel hormone receptor modulator PT150 has unique and possibly additive antiviral and immunomodulatory effects – highlighting its potential role in the treatment and prophylaxis of coronavirus disease (COVID-19).

14 Jul 2020

People with accelerated biological age at increased risk of COVID-19 symptom severity and mortality

Now, a new study published on the preprint server medRxiv in July 2020 discusses the explanation in terms of the biological aging markers in patients with severe disease, rather than the chronological age.

13 Jul 2020

No unique viral sequences found in pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2

In contrast to previous hypotheses, researchers from the University College London and Great Ormond Street Hospital for Children NHS Foundation Trust found no evidence of unique viral sequences from patients with pediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS). Their study is published on the medRxiv* preprint server.

12 Jul 2020

Increasing level of SARS-CoV-2 detected in Montpellier wastewater

Researchers at The French National Centre for Scientific Research have identified a recent increase in the amount of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) RNA at the main wastewater treatment plant (WWTP) of the Montpellier metropolitan area.

12 Jul 2020

WHO confirms 'emerging evidence' of airborne coronavirus

Scientists from around the world wrote a letter to the World Health Organization (WHO), urging the agency to acknowledge that the novel coronavirus is airborne. More than 230 scientists presented evidence that people can catch the virus from droplets floating in the air.

9 Jul 2020

Pigs and chickens not susceptible to SARS-CoV-2

A team of researchers in Germany aimed to investigate the susceptibility of potential animal hosts and the risk of zoonosis spill-over infections, which are illnesses transmitted to humans from animals. On the other hand, reverse zoonosis pertains to infections in humans that jump to animals.

9 Jul 2020

A biomaterial vaccine for SARS-CoV-2 - quick and scalable

A recent 'tour-de-force' research endeavor, led by scientists from Harvard University, explored the propensity of a biomaterial vaccine based on mesoporous silica rods to spawn highly protective humoral responses against relevant antigens of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

8 Jul 2020

Evolutionary snapshot reveals genetic stability of SARS-CoV-2

A multinational study currently available on the bioRxiv preprint server shows that in the early large genome of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) only a handful of amino acids are exchanged, implying a relatively low mutation rate and selection pressure.

7 Jul 2020

SARS-CoV-2 detected in Santiago, Chile wastewater with very little loss of viral RNA

A preliminary report from Chile describes the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in sewage as a sensitive method to assess the circulation of viruses within a community.

7 Jul 2020

Viral and bacterial co-infections are pervasive in severe COVID-19 patients

A large group of researchers from China recently characterized microbial co-infections in the respiratory tract of hospitalized coronavirus disease (COVID-19) patients and demonstrated a high prevalence of both viral and bacterial co-infections – particularly in individuals presenting with severe disease.

6 Jul 2020